Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab.
Natalizumab, an effective treatment for MS, has been shown to exacerbate neuromyelitis optica (NMO) with aquaporin-4 antibodies, but whether this is the case in antibody negative NMO and atypical MS/NMO spectrum disorder overlap syndromes is unknown. We describe a patient with a relapsing optico-spi...
Main Authors: | Kitley, J, Evangelou, N, Küker, W, Jacob, A, Leite, M, Palace, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2014
|
Similar Items
-
Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab
by: Kitley, J, et al.
Published: (2014) -
Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes
by: Juryńczyk, M, et al.
Published: (2015) -
Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.
by: Matthews, L, et al.
Published: (2013) -
Diagnosis of neuromyelitis optica (NMO) spectrum disorders: Is MRI obsolete?
by: Downer, J, et al.
Published: (2012) -
Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?
by: Downer, J, et al.
Published: (2012)